Biothera’s Imprime PGG(R) Improves Survival in KRAS Mutant Colorectal Cancer Patients

June 23, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BARCELONA--(BUSINESS WIRE)--Biothera will present data from its Phase II clinical trial in stage IV KRAS mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25.

Twitter
LinkedIn
Facebook
Email
Print

Europe